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ing enzyme involved in primary and intermediary metab-The Modular Approach
olism. After determining that approximately 4.5% of allto Ligand Discovery the sequences found in the Swiss-Prot protein database
are NAD(P)-utilizing enzymes, a cluster analysis on 288
oxidoreductase crystal structures helped the authors to
further classify the oxidoreductases into pharmacofami-
Identifying specific protein-ligand interactions is a lies [5]. Pharmacofamilies are defined as proteins related
long-standing problem in drug discovery and chemical by sequence, NAD cofactor geometry, and protein fold.
biology, which is only exacerbated by the abundance Interestingly, the two largest families only differ by the
of uncharacterized proteins revealed by genomics. orientation of the nicotinamide ring relative to the ribose
Last month in Chemistry Biology, Sem et al. described with antiorientation predominating (cofactor geometry,
a powerful technique for rapidly screening protein vide supra).
families for ligands [1]. With the pharmacofamilies identified and by using the
NAD cofactor as a starting point, a pharmacophore map
Molecular targeting of specific proteins by small mole- of the cofactor is used to create a model to help identify
cules lies at the very heart of the interface between commercially available reagents capable of binding to
chemistry and biology. If the protein in question is a the enzyme. Competitive binding studies identified sev-
validated therapeutic target, we call this process drug eral common ligand mimics (CLM) that bind within the
discovery. In the case of proteins of unknown function, cofactor site of dihydrodipicolinate reductase (DHPR),
finding a pharmacological tool or probe to investigate an oxidoreductase essential for cell wall synthesis in
the target can be an excellent first step toward deci- Mycobacterium tuberculosis. Further screening of the
phering protein function in a larger, biological context. CLMs against members of the same pharmacofamily
More often, small molecule tools provide orthogonal revealed one compound that possessed crossreactivity
approaches to compliment the more biological methods across the family, in essence identifying a privileged
for elucidating protein function (e.g., siRNA) [2]. The ligand for this class of oxidoreductase enzymes.
difficulty, of course, is faced in finding these tools in a This is where the structure-guided approach becomes
rapid and efficient fashion. important. By using the cofactor as a reference ligand,
Traditionally, the way researchers have tackled this Sem’s previously reported technique, NMR SOLVE
problem has been to perform large, high throughput (structurally oriented library valency engineering), is
screens of structurally varied collections of small mole- used to map key amino acid residues of the enzyme
cules to look for an effect on the protein of interest. involved in cofactor binding [6]. Once the key sites are
Unfortunately, this strategy is resource intensive and identified by changes in chemical shift, the residues can
relies a bit on serendipity; in short, it is neither rapid nor be used as reference points to determine the binding
efficient. If detailed structural information of the protein and orientation of the CLMs. The beauty of this method
target is available (e.g., X-ray structure or NMR struc- lies in the fact that no 3D structure of the overall enzyme
ture), then more direct structure-based methods can be is needed; only information illustrating key peaks at sites
used. However, resolving the 3D structure of a protein critical for small molecule binding is necessary. Further-
is not a trivial matter; not all proteins crystallize and more, NMR is sensitive to changes in chemical shift,
NMR approaches are size limited [3]. In last month’s allowing detection of weak binders that could easily be
issue of Chemistry & Biology, Sem and colleagues dem- missed by functional assays. In this study, Sem and
onstrated a modular, structure-guided approach for rap- colleagues focus on DHPR, a homotetrameric complex
idly identifying new ligands for a family of proteins [1]. of 170 kDa, which is far too large for resolving com-
The modular nature of the approach stems from the plete 3D structure by using current NMR techniques!
fact that protein function and thus structure has been By using the “privileged” CLM as an anchor point,
conserved evolutionarily. Presently, there are approxi- carefully chosen chemical building blocks are chemi-
mately 600 known protein structural domains and esti- cally ligated to the CLM core with the hope of identifying
mates based on genome sequencing projects predict molecules that offer specificity within the pharmacofam-
that this number could rise to 8000 distinct folds [4]. By ily. This takes advantage of the fact that the cofactor
using protein domains as the fundamental unit of protein binding site is adjacent to a specificity site usually occu-
structure, the rationale employed by the Sem group ar- pied by the metabolite upon which the enzyme works.
gues that similar domains should have a propensity to Any building blocks with affinity for the adjacent binding
bind similar pharmacophores, offering a shortcut to iso- site should dramatically increase the overall affinity of
late ligand classes most likely to be useful across protein the new ligand as a result of the “chelate effect,” i.e., a
families. In this study, they chose the oxidoreductase reduced entropic penalty upon binding of a multidentate
family of proteins to test this hypothesis. ligand [7]. In the case of DHPR, the current study re-
The process begins by distilling information from bio- vealed a novel structure with an affinity greater than
informatic analysis of protein sequence databases to two orders of magnitude better than the original CLM.
identify members of the oxidoreductase family of pro- Furthermore, this small molecule has a dramatically
lower affinity for the close oxidoreductase relatives lac-teins, a nicotinamide adenine dinucleotide (NAD)-utiliz-
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